<DOC>
	<DOCNO>NCT00020488</DOCNO>
	<brief_summary>RATIONALE : Drugs use chemotherapy use different way stop tumor cell divide stop grow die . Combining one drug may kill tumor cell . PURPOSE : Phase I trial study effectiveness combination chemotherapy treat patient advance solid tumor .</brief_summary>
	<brief_title>Combination Chemotherapy Treating Patients Who Have Advanced Solid Tumors</brief_title>
	<detailed_description>OBJECTIVES : - Determine recommend phase II dose irinotecan , leucovorin calcium , fluorouracil patient advance solid tumor . - Determine toxic effect regimen patient . - Determine pharmacokinetic pharmacodynamic profile irinotecan fluorouracil patient treat regimen . - Determine correlation polymorphism promoter region thymidylate synthase gene clinical toxicity response patient treat regimen . - Determine correlation polymorphism uridine diphosphate glucuronosyltransferase 1A1 gene promoter extent SN-38 glucuronidation severity diarrhea patient treat regimen . - Assess anti-tumor activity regimen patient . OUTLINE : This dose-escalation study irinotecan fluorouracil . Patients receive irinotecan IV continuously 24 hour day 1 15 leucovorin calcium IV 30 minute follow fluorouracil IV continuously 48 hour day 2 16 . Treatment repeat every 28 day least 2 course absence disease progression unacceptable toxicity . Cohorts 3-6 patient receive escalate dos irinotecan maximum tolerate dose ( MTD ) determine . Once MTD irinotecan determine , additional cohort receive escalate dos fluorouracil MTD determine . The MTD define dose precede 2 3 2 6 patient experience dose-limiting toxicity . PROJECTED ACCRUAL : Approximately 40 patient accrue study within 20 month .</detailed_description>
	<mesh_term>Irinotecan</mesh_term>
	<mesh_term>Fluorouracil</mesh_term>
	<mesh_term>Levoleucovorin</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Histologically confirm advanced solid tumor fail standard therapy standard therapy exist Locally advanced , unresectable , primary recurrent disease OR Metastatic disease Previously untreated disease allow provided regimen represent reasonable firstline therapy No leukemia lymphoma No primary CNS malignancy CNS metastases PATIENT CHARACTERISTICS : Age : 18 Performance status : ECOG 02 Life expectancy : Not specify Hematopoietic : Absolute granulocyte count least 2,000/mm^3 Platelet count least 100,000/mm^3 Hepatic : Bilirubin great 1.6 mg/dL AST/ALT great 4 time upper limit normal Renal : Creatinine great 1.6 mg/dL Other : Not pregnant nursing Negative pregnancy test Fertile patient must use effective contraception HIV negative No serious concurrent illness would preclude study No active infection require IV antibiotic No known hypersensitivity irinotecan No mark intolerance fluorouracil PRIOR CONCURRENT THERAPY : Biologic therapy : More 4 week since prior immunotherapy recover Chemotherapy : More 4 week since prior chemotherapy ( least 6 week nitrosoureas mitomycin ) recover Prior shortinfusion irinotecan allow Prior fluorouracil allow Endocrine therapy : Not specify Radiotherapy : At least 2 week since prior radiotherapy recover At least 8 week since prior strontium chloride Sr 89 Surgery : Recovered prior surgery Other : No concurrent cimetidine</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>September 2003</verification_date>
	<keyword>unspecified adult solid tumor , protocol specific</keyword>
</DOC>